Patents by Inventor Erkki Ruoslahti

Erkki Ruoslahti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210188909
    Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
    Type: Application
    Filed: June 1, 2020
    Publication date: June 24, 2021
    Applicant: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
  • Publication number: 20200368365
    Abstract: Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.
    Type: Application
    Filed: April 27, 2020
    Publication date: November 26, 2020
    Inventors: Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
  • Publication number: 20200282013
    Abstract: Methods and compositions comprising iRGD co-administered with cytokines for treating cancer are provided.
    Type: Application
    Filed: March 6, 2020
    Publication date: September 10, 2020
    Inventors: Harri Jarvelainen, Erkki Ruoslahti
  • Publication number: 20200268832
    Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
    Type: Application
    Filed: December 9, 2019
    Publication date: August 27, 2020
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
  • Publication number: 20200268910
    Abstract: Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 27, 2020
    Inventors: Tambet TEESALU, Pablo SCODELLER, Erkki RUOSLAHTI
  • Publication number: 20200190142
    Abstract: Disclosed are compositions and methods useful for targeting molecules to activated macrophages, such as tumor associated macrophages. The compositions and methods are based on peptide sequences, such as AMT peptides, that home to activated macrophages. The disclosed homing to activated macrophages is useful for delivering therapeutic and detectable agents to cells and tissues where immune system effects or inflammation are occurring.
    Type: Application
    Filed: May 1, 2018
    Publication date: June 18, 2020
    Inventors: Hongbo Pang, Erkki Ruoslahti
  • Patent number: 10669311
    Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: June 2, 2020
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
  • Publication number: 20200156935
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Application
    Filed: July 29, 2019
    Publication date: May 21, 2020
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Patent number: 10653797
    Abstract: Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 19, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
  • Patent number: 10500246
    Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: December 10, 2019
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
  • Patent number: 10370245
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: August 6, 2019
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara
  • Publication number: 20190134211
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Application
    Filed: August 7, 2018
    Publication date: May 9, 2019
    Inventors: Masanobu Komatsu, David Mann, Erkki Ruoslahti
  • Publication number: 20190022239
    Abstract: Provided herein are biomolecule conjugates, and methods of use thereof, wherein the conjugate comprises a cytokine, typically an immunopotentiating cytokine, and a peptide comprising or consisting of the sequence CSGRRSSKC (SEQ ID NO:1). Biomolecule conjugates of the invention find application, inter alia, in the treatment of turnouts, atherosclerosis and fibrosis, and the degradation of ECM associated therewith. Also provided herein are uses of a peptide comprising or consisting of the sequence of SEQ ID NO:1, optionally linked to a delectable agent and/or a carrier, in the detection and/or localisation of tumour, atherosclerotic and fibrotic tissue.
    Type: Application
    Filed: January 19, 2017
    Publication date: January 24, 2019
    Applicants: The University of Western Australia, Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Juliana Binti HAMZAH, Ruth Annelore GANSS, Erkki RUOSLAHTI, Hector R. BILIRAN, Jr.
  • Publication number: 20190022170
    Abstract: Compositions and methods useful for delivery of targeted therapies for pulmonary arterial hypertension, sepsis, cancer and cachexia. The compositions and methods are based on peptide pharmacophores that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. Peptide pharmacophores may selectively target tumor vasculature, regenerating tissue, wounded tissue, inflamed tissue, fibrotic tissue, remodeled tissue, tissue characterized by elevated heparanase levels, and have the ability to internalize into such diseased cells.
    Type: Application
    Filed: August 4, 2015
    Publication date: January 24, 2019
    Inventors: David Mann, Erkki Ruoslahti, Masanobu Komatsu
  • Patent number: 10179801
    Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences, such as truncated LyP-1 peptides, that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: January 15, 2019
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara, Lise Roth
  • Publication number: 20180303898
    Abstract: Disclosed are compositions and methods for treatment of atherosclerosis and atherosclerotic plaques. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerosis. In some forms, the compositions and methods can prevent, inhibit, or reduce atherosclerotic plaques. In particular, compositions comprising a plaque-homing element, a CendR-activating element, and a plaque-inhibiting element are disclosed.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 25, 2018
    Applicant: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Erkki Ruoslahti, Tambet Teesalu, Lauri Paasonen
  • Publication number: 20180296696
    Abstract: Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.
    Type: Application
    Filed: September 2, 2016
    Publication date: October 18, 2018
    Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Erkki RUOSLAHTI, Aman MANN, Pablo SCODELLER, Sazid HUSSAIN
  • Publication number: 20180244720
    Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
    Type: Application
    Filed: April 22, 2016
    Publication date: August 30, 2018
    Applicant: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
  • Patent number: 10039838
    Abstract: Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: August 7, 2018
    Assignees: Vascular Biosciences, Sanford-Burnham Medical Research Institute
    Inventors: Masanobu Komatsu, David Mann, Erkki Ruoslahti
  • Publication number: 20170246236
    Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: December 12, 2016
    Publication date: August 31, 2017
    Inventors: Lilach Agemy, Dinorah Friedmann-Morvinski, Venkata Ramana Kotamraju, Erkki Ruoslahti, Kazuki Sugahara, Inder Verma